On June 9, WuXi AppTec (02359.HK) fell 4.86% in regular trading, trading at 114.2 HKD/share, with trading volume of 55.34 million HKD.

The decline extends a multi-day selloff driven by persistent institutional selling pressure. Morgan Stanley recently reduced its long position in WuXi AppTec H-shares from 5.09% to 4.43% as of June 2, following a sharp cut from 7.72% to 4.27% on May 21. Meanwhile, WuXi system founder Li Ge executed his 14th reduction of WuXi Biologics shares, offloading approximately 82.94 million shares at 26.6 HKD per share through Morgan Stanley, raising roughly 2.2 billion HKD.

The broader Life Sciences Tools and Services sector is under pressure, with WuXi Biologics down 0.53%, WuXi XDC down 1.75%, and XtalPi down 1.69%. Policy headwinds including tightened volume-based procurement regulations and medical insurance catalog adjustments continue to suppress valuation recovery across the pharmaceutical sector. Although the company has been actively repurchasing H-shares, the cumulative selling pressure from both institutional investors and insiders remains dominant in the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)